Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.40 |
| ▸ | AKT1 | P31749 | 2/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10328224 | 0.92 | PIK3CA (0.41) | PIK3CAAKT1MTORHSP90AA1EGFR | |
| SCHEMBL584173 | 0.89 | PIK3CA (0.41) | PIK3CAAKT1MTORHSP90AA1JAK1 | |
| SCHEMBL7880719 | 0.86 | CHEK1 (0.42) | PIK3CAAKT1MTOREGFRFGFR2 | |
| SCHEMBL6891386 | 0.86 | CHEK1 (0.47) | PIK3CAAKT1MTOREGFRFGFR2 | |
| SCHEMBL2704521 | 0.85 | MTOR (0.40) | PIK3CAAKT1MTORHSP90AA1EGFR | |
| SCHEMBL7882545 | 0.85 | PIK3CA (0.40) | PIK3CAAKT1MTORHSP90AA1EGFR | |
| SCHEMBL10238717 | 0.85 | PIK3CA (0.37) | PIK3CAAKT1MTOREGFRFGFR2 | |
| SCHEMBL7883729 | 0.85 | PIK3CA (0.37) | PIK3CAAKT1MTOREGFRFGFR2 | |
| SCHEMBL2685713 | 0.84 | CHEK1 (0.45) | PIK3CAAKT1MTOREGFRFGFR2 | |
| SCHEMBL10234765 | 0.84 | PIK3CA (0.39) | PIK3CAAKT1MTORHSP90AA1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8591943-B2 | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | PIK3CA 34/4885AKT1 230/4885MTOR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.